This review examines the evolution of intravenous (IV) iron therapies, focusing on newer formulations such as ferumoxytol, ferric carboxymaltose, and iron isomaltoside. These agents possess more stable iron-carbohydrate complexes, allowing for higher single-dose administrations with reduced labile iron release, thereby minimizing infusion-related adverse events. Their enhanced safety profiles and dosing
